interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Atrasentan Hydrochloride

Generic competition · all medicines · read 12 November 2026

Is there a generic of Atrasentan Hydrochloride, and who makes it?

Atrasentan Hydrochloride appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Atrasentan Hydrochloride1 dosage-form group in the Orange Book
0generic makers listed
  1. Atrasentan Hydrochloride appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Vanrafia. No generic is listed as marketed.

20202025203020352040204501brand 2025data datePatent 8623819 listed to expire 22 August 2028Patent 11874283 listed to expire 18 February 2032Patent 9364458 listed to expire 7 July 2034Patent 10016393 listed to expire 7 July 2034Patent 12370174 listed to expire 16 December 2040Patent 12121509 listed to expire 16 December 2040Patent 11998526 listed to expire 16 December 2040Patent 11491137 listed to expire 16 December 2040Patent 12521369 listed to expire 2 March 2041Patent 12582631 listed to expire 25 March 2043Exclusivity NCE to 2 April 2030
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 2 April 2030Exclusivity NCE Vanrafia
  • 22 August 2028Patent 8623819
  • 18 February 2032Patent 11874283
  • 7 July 2034Patent 9364458 drug product
  • 7 July 2034Patent 10016393 drug product
  • 16 December 2040Patent 12370174
  • 16 December 2040Patent 12121509
  • 16 December 2040Patent 11998526
  • 16 December 2040Patent 11491137

2 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.